Mereo Biopharma Group Plc ADR (NASDAQ: MREO) kicked off on Friday, down -9.95% from the previous trading day, before settling in for the closing price of $2.21. Over the past 52 weeks, MREO has traded in a range of $2.11-$5.02.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -40.00%. While this was happening, its average annual earnings per share was recorded 26.19%. With a float of $139.69 million, this company’s outstanding shares have now reached $155.15 million.
Considering the fact that the conglomerate employs 36 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Mereo Biopharma Group Plc ADR (MREO) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Mereo Biopharma Group Plc ADR is 8.04%, while institutional ownership is 66.28%. The most recent insider transaction that took place on Sep 13 ’24, was worth 253,454. In this transaction Chief Executive Officer of this company sold 60,046 shares at a rate of $4.22, taking the stock ownership to the 808,921 shares. Before that another transaction happened on Sep 12 ’24, when Company’s Chief Executive Officer sold 28,611 for $4.47, making the entire transaction worth $127,968. This insider now owns 868,967 shares in total.
Mereo Biopharma Group Plc ADR (MREO) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.01 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 26.19% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 17.79% during the next five years compared to 34.82% growth over the previous five years of trading.
Mereo Biopharma Group Plc ADR (NASDAQ: MREO) Trading Performance Indicators
Take a look at Mereo Biopharma Group Plc ADR’s (MREO) current performance indicators. Last quarter, stock had a quick ratio of 5.40.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.29, a number that is poised to hit -0.01 in the next quarter and is forecasted to reach -0.03 in one year’s time.
Technical Analysis of Mereo Biopharma Group Plc ADR (MREO)
Compared to the last year’s volume of 1.28 million, its volume of 1.49 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 21.85%. Additionally, its Average True Range was 0.18.
During the past 100 days, Mereo Biopharma Group Plc ADR’s (MREO) raw stochastic average was set at 2.43%, which indicates a significant decrease from 7.50% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 78.45% in the past 14 days, which was higher than the 64.44% volatility it showed in the past 100 days.
Nevertheless, the first resistance level for the watch stands at $2.1300 in the near term. At $2.2700, the stock is likely to face the second major resistance level. The third major resistance level sits at $2.3700. If the price goes on to break the first support level at $1.8900, it is likely to go to the next support level at $1.7900. Now, if the price goes above the second support level, the third support stands at $1.6500.
Mereo Biopharma Group Plc ADR (NASDAQ: MREO) Key Stats
The company with the Market Capitalisation of 308.75 million has total of 155,146K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -43,250 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -7,050 K.
